Article Text

PDF
SAT0148 Short and Long-Term Biological Therapy in Refractory Uveitis of Behcet’S Syndrome. Multicenter Study of 108 Patients
  1. V. Calvo-Río1,
  2. R. Blanco1,
  3. E. Beltrán2,
  4. J. S-Bursón3,
  5. M. Mesquida4,
  6. A. Adán4,
  7. M. Hdez-Grafella2,
  8. E. Valls5,
  9. L. Mtnez-Costa5,
  10. A. Sellas6,
  11. M. Cordero-Coma7,
  12. M. D-Llopis8,
  13. D. Salom8,
  14. J. G-Serrano9,
  15. N. Ortego9,
  16. J. Herreras10,
  17. A. Fonollosa11,
  18. A. Aparicio12,
  19. O. Maíz13,
  20. A. Blanco13,
  21. I. Torre14,
  22. C. Fdez-Espartero15,
  23. V. Jovani16,
  24. D. Peitado17,
  25. E. Pato18,
  26. J. Cruz19,
  27. C. Fdez-Cid19,
  28. E. Aurrecoechea20,
  29. M. García21,
  30. M. Caracuel22,
  31. C. Montilla23,
  32. A. Atanes24,
  33. F. Francisco25,
  34. S. Insua26,
  35. S. Glez-Suárez27,
  36. A. Schez-Andrade28,
  37. F. Gamero29,
  38. L. Linares30,
  39. F. Romero31,
  40. J. García32,
  41. J. Loricera1,
  42. M. G-Gay1
  1. 1Valdecilla, Santander
  2. 2HGU, Valencia
  3. 3Valme, Sevilla
  4. 4Clinic, Barcelona
  5. 5Peset, Valencia
  6. 6Hebron, Barce.
  7. 7H, León
  8. 8Fe, Valencia
  9. 9Cecilio, Granada
  10. 10 IOBA, Valladolid
  11. 11Cruces, Bilbo
  12. 12H, Toledo
  13. 13H, Donosti
  14. 14Basurto, Bilbo
  15. 15H, Móstoles
  16. 16H, Alicante
  17. 17Paz
  18. 18Carlos, Madrid
  19. 19H, Pontev.
  20. 20H, Torrelav.
  21. 21Princesa, Madrid
  22. 22H, Córdoba
  23. 23H, Salaman.
  24. 24HUCA, Coruña
  25. 25Negrín, Palmas
  26. 26H, Santiago
  27. 27H, Gijón
  28. 28H, Lugo
  29. 29Alcantara, Cacer.
  30. 30H, Murcia
  31. 31FJD
  32. 3212Octubre, Madrid, Spain

Abstract

Objectives To assess response to biological therapy in uveitis associated to Behçet´s syndrome (BS) refractory to standard immunosuppressants (IS).

Methods Study of 108 patients from 32 hospitals. All of them presented inadequate response to at least 1IS. Inflammation was evaluated according to SUN (Am J Ophthalmol 2005); macular thickness by optical coherence tomography (OCT). Results were expressed as mean±SD, or median [25t-75th(IQR)]. Comparisons were made between baseline and 1st week, 1st, 6th month, 1st, 2nd, 3rd and 4th year (Wilcoxon).

Results We studied 108 patients/193 affected eyes (59M/49W); mean age 38.2±10.4 years (range 10-67). Before biologic onset they had received iv MethylP (32 cases), CyA (91), MTX (53) or AZA (62). Anti-TNF was 1st choice: infliximab (IFX)(65 cases) and adalimumab (ADA)(43); in monotherapy (22 cases) or in combination: CyA (49 cases), MTX (20), AZA (15), Micophenolate (1), or tacrolimus (1). In refractory or toxicity to 1st biologic was used; Golimumab (4 cases), Tocilizumab (1), RTX (1) and ETN (1). Anti-TNF follow-up was 35.4±20.2 months. Tyndall, vitritis and OCT showed a rapid and significant improvement at the 1st week. From biological onset to 2 years of follow-up patients showed an improvement of Tyndall from a median [IQR] of 1 [0-2] to 0 [0-0] (p<0.001), vitritis, 1 [0-2] to 0 [0-0] (p<0.001). At basal, 51 patients,(79 eyes) had macular thickening (OCT>250μ) and 31 (44 eyes) had cystoid macular edema (CME)(OCT>300μ). CME improved from 422.2±118.2 to 280.5±56.4 microns at 2 years (p<0.001).

Conclusions Biological therapy, especially IFX and ADA, yields short and long-term efficacy in uveitis refractory to standard IS in BS.

Disclosure of Interest None Declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.